TEC Edmonton is seeking collaborative development and licensing partners for novel radio/chemosensitizing agents. Researchers at the University of Alberta have identified potent small molecule inhibitors of a new DNA repair target, human polynucleotide kinase/phosphatase (PNKP). PNKP is an importan.....
[Detail]
TEC Edmonton is seeking collaborative development and licensing partners for a novel PET imaging agent. Dr. Chris Cheeseman and colleagues at the University of Alberta have recently designed and synthesized a new class of fluorinated fructose compounds with the potential to be used during in vivo P.....
[Detail]
TEC Edmonton is seeking licensing partners for a novel precursor that simplifies synthesis of [18F]FAZA, a PET radiotracer that selectively accumulates in hypoxic cells. It was invented and developed at the Cross Cancer Institute of Alberta and is currently used in several medical centers to assess .....
[Detail]
